Speaker and Planner Financial Disclosures

Disclosures

ASRS adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

The individuals below have responded that they have no relevant financial relationships with ineligible entities:

Speakers

  • Sharam Danesh, MD                                                                     
  • Kurt Defenbaugh, MBA
  • Ankit Desai                                                                                        
  • Jack Flanagan, MBA, CPA
  • Alyssa Garcia                                                                                     
  • Tiffany Harrison
  • Aamer Hayat                                                                                      
  • Scott Heintzeman, MBA
  • Cameron Javid, MD, MBA, FACS                                           
  • Brandon Johnson, MD
  • Linda Lam, MD, MBA                                                                     
  • Mike Lyons, MHRIR
  • Kim Maccarone                                                                                
  • Shelly McClellan
  • Christine McCutcheon                                                                 
  • Gayatri Reilly, MD
  • Michael Romano, MHA                                                               
  • Adiel Smith, MD, FASRS                                
  • Heather Thomas                                                                              
  • Joy Woodke, COE, OSC, OSCR
  • Mike White

Planning Committee Members

  •  Michael Lai, MD, PhD
  • Tushar Ranchod, MD

 The individuals below have disclosed the following financial relationships with ineligible entities:

 Speakers: Name of Ineligible Company/Nature of Relationship

 Ashkan Abbey, MD, FASRS, FAAO: Eyepoint Pharmaceuticals, Principal Investigator, Consultant; Alcon, Consultant, Speaker Bureau; Alimera Sciences, Consultant, Speaker Bureau; Allergan, Consultant, Principal Investigator, Speaker Bureau; Genentech, Consultant, Speaker Bureau; Regeneron, Speaker Bureau

Margaret Chang, MD, MS: Genentech, Consultant; RegenXBio, Consultant; Opthea, Principal Investigator; Regeneron, Principal Investigator; Novartis, Principal Investigator; Allergan, Principal Investigator; Mylan, Principal Investigator; Ophthotech, Consultant; NGM, Principal Investigator

Kevin Dement: Brainscope, Private Stock; DynamiCare, Private Stock; ePharmix/CareSignal, Private Stock; Titanium Investment, Private Stock; Mednition, Private Stock; Octiva, Private Stock; HeartFlow, Private Stock

Roberto Diaz: Alimera, Consultant

J. Michael Jumper, MD, FASRS: EyeBio, Advisory Board Member; DORC, Speaker Bureau; Novartis, Principal Investigator; ReGenXBio, Principal Investigator; Genentech, Principal Investigator; Ionis Pharamaceuticals, Principal Investigator; Boehringer Ingleheim, Principal Investigator

Robert Lea, MBA: Outlook, Advisory Board Member; Regeneron, Consultant; Iveric, Consultant

Deborah Leemaster: Retina Consultants of America, Employee; EssilorLuxottica, Public Stock, Employee

Claire Murphy, OSC, OCS, OCSR: Regeneron, Speaker Bureau

Joel Pearlman, MD, PhD: Genentech, Principal Investigator; Roche, Principal Investigator; Novartis, Principal Investigator; Oxurion, Principal Investigator; Glaxo Smith Kline, Principal Investigator; Regeneron, Principal Investigator; Kodiak, Principal Investigator; Boehringer Ingelheim, Principal Investigator; Annexon, Principal Investigator; Sandoz, Principal Investigator; Opthea, Principal Investigator; EyePoint, Principal Investigator, Advisory Board Member; 4DMT, Principal Investigator; Bayer, Principal Investigator

Alison Ratliff, MBA: Genentech, Advisory Board Member, Speaker Bureau; Regeneron, Advisory Board Member, Speaker Bureau; RegenXBio, Consultant; Cardinal, Advisory Board Member; Apellis, Advisory Board Member; Coherus, Advisory Board Member, Speaker Bureau; Iveric, Advisory Board Member; Outlook Therapeutics, Advisory Board Member

Ankoor Shah, MD, FASRS: Regenxbio, Consultant; Bausch + Lomb, Consultant

Veeral Sheth, MD, MBA, FASRS, FACS: Genentech, Speaker Bureau; Alimera, Speaker Bureau, Consultant; Genentech, Consultant; Novartis, Consultant; EyePoint, Consultant; IvericBio, Consultant; Graybug, Consultant; Allergan, Principal Investigator; Ophthea, Principal Investigator; Oxurion, Principal Investigator; Recens Medical, Principal Investigator; Roche, Principal Investigator; RegenxBio; EyePoint, Principal Investigator; Ionis, Principal Investigator; Novartis, Principal Investigator

Jayanth Sridhar, MD: Alcon, Consultant; Genentech, Consultant; DORC, Consultant; Regeneron, Consultant; Allergan, Consultant; Apellis, Consultant

John Thompson, MD: Genentech/Roche, Principal Investigator; Ocutrx Technologies Inc., Stock; Alexion Pharmaceuticals, Principal Investigator; DHR Pro LLC, Private Stock

Scott Walter, MD, MSc: Genentech, Speaker Bureau, Spark Therapeutics, Speaker Bureau; Novartis, Advisory Board Member; Castle Biosciences, Advisory Board Member; Apellis, Speaker Bureau; Bausch & Lomb, Advisory Board Member, Speaker Bureau, Steering Committee Member; EyePoint, Advisory Board Member; Regeneron, Advisory Board Member; Roche, Speaker Bureau

Keith Warren, MD: Allergan, Advisory Board Member

Kristin Yockus, BA, MPH: Genentech, Advisory Board Member; Regeneron, Advisory Board Member; IPN Solutions, Advisory Board Member; Coherus, Advisory Board Member

Sarwar Zahid, MD: Alimera, Consultant; Allergan, Consultant

 Planning Committee Members: Name of Ineligible Company/Nature of Relationship

 Stephanie Collins, MBA: Regeneron, Speaker Bureau

 Vivienne Hau, MD, PhD:Genentech/Roche, Principal Investigator; Regeneron, Principal Investigator; Novartis, Principal Investigator  

 Gretchen Poffenberger, MBA:Outlook Pharmaceuticals, Advisory Board Member

 Charles Wykoff, MD, PhD, FASRS: AbbVie, Consultant; Adverum, Consultant, Principal Investigator; Aerie, Consultant, Principal Investigator; AffaMed, Principal Investigator; AGTC, Consultant; Alcon, Consultant; Alimera, Consultant, Principal Investigator; Allergan, Consultant; Aldeyra, Principal Investigator; Allgenesis, Consultant, Principal Investigator; Alnylam, Consultant; Annexon, Consultant; Apellis, Consultant; Alkahest, Principal Investigator; Allergan, Principal Investigator; Alexion, Principal Investigator; Amgen, Principal Investigator; Annexon, Principal Investigator; Apellis, Principal Investigator; Asclepix, Principal Investigator; Arrowhead, Consultant; Bausch + Lomb, Consultant; Bayer, Consultant, Principal Investigator; Bionic Vision Technologies, Consultant; Boehringer Ingelheim, Consultant, Principal Investigator; Chengdu Kanghong Biotechnologies, Consultant, Principal Investigator; Cholgene, Consultant; Clearside, Consultant, Principal Investigator; Curacle, Consultant; Eyepoint, Consultant, Principal Investigator; Foresite, Consultant; Frontera, Consultant; Gemini, Principal Investigator; Genentech, Consultant, Principal Investigator; Graybug, Principal Investigator; Gyroscope, Consultant, Principal Investigator; IACTA, Consultant; IONIS, Principal Investigator; IRENIX, Principal Investigator; IVERIC Bio, Consultant; Janssen, Consultant; Kato, Consultant; Kiora, Consultant; Kriya, Consultant; Kodiak, Consultant, Principal Investigator; LMRI, Principal Investigator; Merck, Consultant, Stock Options; Nanoscope, Consultant, Principal Investigator; Neurotech, Principal Investigator; THEA, Consultant; NGM, Consultant, Principal Investigator; Notal Vision, Consultant; Novartis, Consultant, Principal Investigator; OccuRx, Consultant; Occuphire, Principal Investigator; OccuTerra, Consultant, Principal Investigator; Ocular Therapeutix, Consultant, Principal Investigator; OliX, Consultant; ONL, Consultant, Stock Options; Opthea, Consultant, Principal Investigator; Oxurion, Principal Investigator; Oyster Point, Principal Investigator; Palatin, Consultant; Perfuse, Consultant; PolyPhotonix, Consultant, Stock Options; RecensMedical, Consultant, Principal Investigator, Stock Options; Regeneron, Consultant, Principal Investigator; Regenxbio, Consultant, Principal Investigator; Roche, Consultant, Principal Investigator; SamChunDang Pharmaceuticals, Principal Investigator Stealth, Consultant; Surrozen, Consultant; Takeda, Consultant, Stock Options; Taiwan Liposome Company, Principal Investigator; TissueGen, Consultant; Xbrane, Principal Investigator; Val, Consultant; Verana, Consultant; Visgenx, Stock Options; Vitanu, Consultant, Stock Options; Ray, Stock Options; Resonance, Consultant; Sandoz, Principal Investigator; 4DMT, Consultant, Principal Investigator; UNITY, Principal investigator; Verily, Principal Investigator; TissueGen, Stock Options; Oxular, Consultant; PercieveBio, Consultant, Principal Investigator; SciNeuro, Consultant; Annexin, Principal Investigator; Curacle, Principal Investigator; GlaxoSmithKline, Principal Investigator; Opthotech, Principal Investigator; Oxular, Principal Investigator